|
Index | - | P/E | - | EPS (ttm) | -6.20 | Insider Own | 0.20% | Shs Outstand | 42.38M | Perf Week | 7.29% |
Market Cap | 653.81M | Forward P/E | - | EPS next Y | -2.54 | Insider Trans | 14.64% | Shs Float | 18.08M | Perf Month | -10.82% |
Income | -81.60M | PEG | - | EPS next Q | -0.61 | Inst Own | 75.00% | Short Float | 5.01% | Perf Quarter | 0.82% |
Sales | 0.80M | P/S | 817.26 | EPS this Y | 75.70% | Inst Trans | 349.30% | Short Ratio | 7.31 | Perf Half Y | -7.99% |
Book/sh | 25.41 | P/B | 0.63 | EPS next Y | 2.70% | ROA | -26.60% | Target Price | - | Perf Year | -1.24% |
Cash/sh | 6.02 | P/C | 2.64 | EPS next 5Y | 9.00% | ROE | -68.70% | 52W Range | 10.50 - 21.68 | Perf YTD | 0.25% |
Dividend | - | P/FCF | - | EPS past 5Y | -7.20% | ROI | -16.20% | 52W High | -26.66% | Beta | 0.06 |
Dividend % | - | Quick Ratio | 11.10 | Sales past 5Y | -59.20% | Gross Margin | - | 52W Low | 51.43% | ATR | 1.12 |
Employees | 96 | Current Ratio | 11.10 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 50.97 | Volatility | 6.68% 7.68% |
Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 75.70% | Profit Margin | - | Rel Volume | 0.91 | Prev Close | 15.24 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Apr 07 AMC | Payout | - | Avg Volume | 123.71K | Price | 15.90 |
Recom | 1.50 | SMA20 | -0.52% | SMA50 | -2.60% | SMA200 | 6.87% | Volume | 112,394 | Change | 4.33% |
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite